{
    "ticker": "NVCR",
    "name": "NovoCure Limited",
    "description": "NovoCure Limited is a global clinical-stage oncology company recognized for its innovative approach to cancer treatment. Founded in 2000 and headquartered in St. Helier, Jersey, NovoCure is dedicated to improving patient outcomes through its proprietary Tumor Treating Fields (TTFields) therapy, which utilizes low-intensity electric fields to disrupt cancer cell division. This novel treatment modality is designed to target specific types of tumors, including glioblastoma and mesothelioma, offering patients a non-invasive option that can be used in conjunction with standard therapies such as chemotherapy and radiation. The company is committed to advancing cancer care and has a robust pipeline of clinical trials aimed at expanding the application of TTFields to various solid tumors. NovoCure's mission is to extend survival and improve the quality of life for patients with cancer, driven by a culture of innovation and scientific rigor. With a growing presence in the oncology market, NovoCure is poised to make significant contributions to cancer treatment and research.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "St. Helier, Jersey",
    "founded": "2000",
    "website": "https://www.novocure.com",
    "ceo": "William Doyle",
    "social_media": {
        "twitter": "https://twitter.com/novocure",
        "linkedin": "https://www.linkedin.com/company/novocure/"
    },
    "investor_relations": "https://investors.novocure.com",
    "key_executives": [
        {
            "name": "William Doyle",
            "position": "CEO"
        },
        {
            "name": "Amit Patel",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Treatment",
            "products": [
                "TTFields for Glioblastoma",
                "TTFields for Mesothelioma"
            ]
        }
    ],
    "seo": {
        "meta_title": "NovoCure Limited | Innovative Cancer Treatment Solutions",
        "meta_description": "Explore NovoCure Limited, a leader in cancer treatment through Tumor Treating Fields therapy. Discover their innovative approach to improving patient outcomes in oncology.",
        "keywords": [
            "NovoCure",
            "Cancer Treatment",
            "Tumor Treating Fields",
            "Oncology",
            "Glioblastoma",
            "Mesothelioma"
        ]
    },
    "faq": [
        {
            "question": "What is NovoCure known for?",
            "answer": "NovoCure is known for its innovative Tumor Treating Fields therapy for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of NovoCure?",
            "answer": "William Doyle is the CEO of NovoCure Limited."
        },
        {
            "question": "Where is NovoCure headquartered?",
            "answer": "NovoCure is headquartered in St. Helier, Jersey."
        },
        {
            "question": "What are NovoCure's main products?",
            "answer": "NovoCure's main products include TTFields therapy for glioblastoma and mesothelioma."
        },
        {
            "question": "When was NovoCure founded?",
            "answer": "NovoCure was founded in 2000."
        }
    ],
    "competitors": [
        "VRTX",
        "CLVS",
        "BMY",
        "MRNA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}